[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.207.116. Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Views 2,421
Citations 0
Correction
August 18, 2015

Incorrect Dose in Figure

JAMA. 2015;314(7):731. doi:10.1001/jama.2015.9237

In the Original Contribution entitled “Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial” published in the July 14, 2015, issue of JAMA,1 an incorrect study drug dose appeared in a figure. In Figure 2, the starting patiromer dose reported as 16.2 in the x-axis for both stratum 1 and stratum 2 in both the left and the right plots should have appeared as 16.8. This article was corrected online.

References
1.
Bakris  GL, Pitt  B, Weir  MR,  et al; AMETHYST-DN Investigators.  Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial. JAMA. 2015;314(2):151-161.
PubMedArticle
×